A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
Conditions: Intrahepatic Cholangiocarcinoma Interventions: Drug: Adebrelimab Sponsors: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bile Duct Cancer | Cancer | Cancer & Oncology | Cholangiocarcinoma | Hospitals | Research